N 3 (188) 2024. P. 34–38

EFFECTIVENESS OF USING SULODEXIDE IN THE COMPLEX TREATMENT OF PATIENTS WITH ARTERIAL HYPERTENSION WITH ACCOMPANYING DIABETES MELLITUS IN THE POST-COVID PERIOD

O. B. Voloshyna, E. A. Zubok, V. O. Zbitnieva, O. V. Chekhlova, I. V. Balashova

Odesa National Medical University, Odesa, Ukraine

DOI 10.32782/2226-2008-2024-3-6

Aim. To study the effectiveness of using sulodexide in the complex treatment of patients with arterial hypertension with accompanying diabetes in the post-COVID period.

Methods. According to the inclusion criteria, 87 patients with hypertension and concomitanttype 2 diabetes participated in the study. Patients were included in the study after having COVID-19 at an average of 57.82±3.2 [46–112] days after the onset of infection. The first, main group, consisted of 45 patients who additionally used sulodexide capsules (250 LO twice a day for 3 weeks) against the background of the basic treatment of hypertension and diabetes. The second (control) group consisted of 44 patients, who received only the basic treatment of hypertension and diabetes.

Results. It was established that the use of sulodexide (250 LO twice a day for 3 weeks) in the complex treatment of patients with hypertension and diabetes in the post-COVID period compared to the control group was accompanied by a reliable disappearance or reduction of the symptoms of the post-COVID syndrome, an additional decrease in blood pressure, a significant decrease in the ankle-brachial index, which indicated improvement in peripheral blood circulation and quality of life of these patients.

Conclusions. Addition of sulodexide capsules to basic therapy in patients with hypertension and concomitant diabetes mellitus contributes to increasing the effectiveness of complex treatment, as evidenced by the reduction of symptoms of long post-COVID syndrome against the background of improvement in the course of comorbid pathology, improvement in the quality of life of patients.

Key words: arterial hypertension, diabetes mellitus, COVID-19, post-COVID period, sulodexide.

BIBLIOGRAPHY

  1. Oluwatoyosi O. Hypertension and Diabetes Comorbidity: Factors that are Associated with their Joint Occurrence. Thesis, Georgia State University. doi: https://doi.org/10.57709/35480760
  2. de Boer IH, Bangalore S, Benetos A. et al. Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care. 2017;40(9):1273-1284. doi: 10.2337/dci17-0026. PMID: 28830958.
  3. Williams B, Mancia G, Spiering W. et al. ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021-3104. doi: 10.1093/eurheartj/ehy339. Erratum in: Eur Heart J. 2019 Feb 1;40(5):475. PMID: 30165516.
  4. Mancia G, Kreutz R, Brunström M. et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874-2071. doi: 10.1097/ HJH.0000000000003480. Epub 2023 Sep 26. Erratum in: J Hypertens. 2024 Jan 1;42(1):194. PMID: 37345492.
  5. Voloshyna O., Zbitneva V., Zubok E. et al. Peculiarities of Arterial Hypertension Course in Patients with Concomitant Diabetes Mellitus in the Post-COVID Period. Lviv clinical bulletin. 2022;1(37)-2(38):75-80.https://doi.org/10.25040/ lkv2022.01-02.075) (In Ukrainian).
  6. Zbitnieva V., Voloshyna O., Balashova I., Zubok E., Dukova O., Kovalchuk L. Peculiarities of ambulatory blood pressure monitoring in patients who have suffered from COVID-19. perspekt. 2023;28(4):71-9. Available from: https://journals. uran.ua/index.php/2307-0404/article/view/294034 (In Ukrainian).
  7. Shah W., Hillman T., Playford E.D., Hishmeh L. Managing the long term effects of COVID-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ. 2021;372:n136. doi: 10.1136/bmj.n136. Erratum in: BMJ. 2022 Jan 19;376:o126. doi: 10.1136/bmj.o126. PMID: 33483331.
  8. Charfeddine S, Ibn Hadj Amor H. et al. Long COVID 19 Syndrome: Is It Related to Microcirculation and Endothelial Dysfunction? Insights From TUN-EndCOV Study. Front Cardiovasc Med. 2021;8:745758. doi: 10.3389/fcvm.2021.745758. PMID: 34917659; PMCID: PMC8670225.
  9. Charfeddine S, Ibnhadjamor H, Jdidi J. et al. Sulodexide Significantly Improves Endothelial Dysfunction and Alleviates Chest Pain and Palpitations in Patients with Long-COVID-19: Insights From TUN-EndCOV Study. Front Cardiovasc Med. 2022;9:866113. doi: 10.3389/fcvm.2022.866113
  10. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-2454. doi: 10.1093/eurheartj/ ehab309. PMID: 34120177; PMCID: PMC8248998.
  11. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Archives of Neurology.1989; 46 (10): 1121–1123.doi: 10.1001/ archneur.1989.00520460115022.
  12. Kos D, Kerckhofs E, Carrea I, Verza R, Ramos M, Jansa J. Evaluation of the Modified Fatigue Impact Scale in four different European countries. Mult Scler. 2005;11(1):76-80. doi: 10.1191/1352458505ms1117oa. PMID: 15732270.
  13. EuroQol Group. EuroQol–a new facility for the measurement of health-related quality of life. Health Policy. 1990;16(3):199-208. doi: 10.1016/0168-8510(90)90421-9. PMID: 10109801.
  14. Antomonov M.Yu. Mathematical processing and analysis of medical and biological data. 2nd edition. K.: Medinform, 2018. 579 p.[in Ukrainian]
  15. Support for independent rehabilitation after diseases related to COVID-19 https://iris.who.int/bitstream/handle/10665/333547/ WHO-EURO-2020-855-40590-54654-ukr.pdf
View article PDF